openPR Logo
Press release

Global Orphan Drugs Market Shares Include: Europe, North America, Asia Pacific and South America

11-03-2017 09:24 AM CET | Health & Medicine

Press release from: Data Bridge Market Research

Orphan Drugs Market by Focusing on Top Companies Globally

Orphan Drugs Market by Focusing on Top Companies Globally

The Global Orphan Drugs Market accounted to USD 113.8 billion in 2016 growing at a CAGR of 7.23% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

The rarest diseases are known as orphan diseases. To treat these types of diseases drugs available are termed as Orphan drugs. These kinds of diseases are usually different and its occurrence rate is very less. Orphan drugs are impacts on small group of the population, as it is mostly genetic in nature.

Major Market Drivers and Restraints:
• Rising prevalence of rare diseases
• Rise in R&D investments
• Expansion of product pipeline by launching new drugs
• Impact of developments in pharmacogenomics
• Government initiatives for the development
• High prices are associated with these drug development

Click & Get Free Sample Report of Global Orphan Drugs Market Visit @ databridgemarketresearch.com/request-a-sample/?dbmr=globa...

Competitive Analysis:

The orphan drugs market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of orphan drugs market for global, Europe, North America, Asia Pacific and South America.

Market Segmentation:

On The Basis Of Product Based: biologics orphan drugs and non-biologics orphan drugs. Biologics orphan drugs is sub segmented into monoclonal antibodies, growth hormones, interferons or interleukins and plasma products.

Have any Query Regarding this Report? Contact us Visit @: databridgemarketresearch.com/speak-to-analyst/?dbmr=globa...

On The Basis Of Disease Type: oncologic, metabolic, hematologic & immunologic, infectious and neurologic.

On The Basis Of Indication: non-Hodgkin lymphoma, acute myeloid leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, Duchenne muscular dystrophy, graft vs host disease and renal cell carcinoma.

On The Basis Of Geography: Orphan Drugs Market Report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.

Major Market Competitors:

Some of the major players operating in orphan drugs market are F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie, AstraZeneca, Baxter, Eli Lilly and Company, Johnson & Johnson Services Inc., Merck KGaA, Novo Nordisk A/S, Sanofi, Bristol-Myers Squibb Company, CELGENE CORPORATION, Alexion, Alnylam Pharmaceuticals, Inc., Amgen Inc., Biogen, Celldex Therapeutics, GlaxoSmithKline plc., Eisai Co., Ltd., Intercept Pharmaceuticals, Inc., Northwest Biotherapeutics, Inc., NewLink Genetics Corporation, Shire, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated and XOMA among others.

For more information about this report visit @ databridgemarketresearch.com/reports/global-orphan-drugs-...

Related Report

Global Ophthalmic Suspension Market – Industry Trends and Forecast to 2024

Global Ophthalmic Suspension Market by Product (Antibiotic, Antifungal, Antibacterial, Steroids, Non-Steroidal Anti-Inflammatory Drugs), By Treatment (Bacterial Infections, Retinal Disorders, Glaucoma, Allergies, Diabetic Eye Disease), By End User (Hospitals, Eye Clinics, Clinics), By Geography – Industry Trends and Forecast to 2024

Read More: databridgemarketresearch.com/reports/global-ophthalmic-su...

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog databridgemarketresearch.com/blog/
Follow us on LinkedIn: www.linkedin.com/company/data-bridge-market-research

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Orphan Drugs Market Shares Include: Europe, North America, Asia Pacific and South America here

News-ID: 800090 • Views: 264

More Releases from Data Bridge Market Research

Global DevSecOps Market worth USD 13.63 billion by 2026| Key Players include- Cy …
The Global DevSecOps Market report provides on inside and out market study and future prospects of the Information and Communication Technology sector business. Global DevSecOps Market is the expected the value of USD 13.63 billion by 2026. The examination covers imperative data which makes the whole report an advantageous resource for overseers, agents, industry authorities, and other key people plan to-access and self-analyzed investigation close by charts and tables to
Global Mobile Medical Apps Market To Grow at a CAGR of 33.7% by 2026 Profiling
This Global Mobile Medical Apps marketing research report assists in planning by providing accurate and state-of-the-art information about the consumer’s demands, their buying preferences, attitudes and their changing tastes about the specific product. To generate this global market research report, the data is collected from the diverse corners of the globe by an experienced team of language resources. Statistical and numerical data covered in the report is represented using
Global Carpets and Rugs Market: Global Industry Growth Forecast Report By Dixie …
Market Analysis: Global Carpets and Rugs Market The Global Carpets and Rugs Market is expected to reach USD 133.15 billion by 2025, from USD 91.95 billion in 2017 growing at a CAGR of 4.5% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2015 & 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. Market Definition: Global
Global 5G Chipset Market Report: Focuses On Top Companies M, Qorvo, Infineon Tec …
The Global 5G Chipset Market is expected to reach USD 0.13 billion by 2025, from USD 21.01 billion in 2017 growing at a CAGR of 49.02% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. Market Definition: Global 5G Chipset Market 5G Chipset network is now in

All 31689 Releases


More Releases for Orphan

US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the
Global Orphan Drug Clinical Pipeline Insight 2022
“Global Orphan Drug Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan
Global Orphan Drugs Market Report: 2016 Edition
A rare disease is the one that occurs uncommonly or rarely in the general population. However, there exists no clear definition for categorizing “rare diseases” and is usually defined on the basis of the prevalence, and some other factors including the severity of disease and availability of treatment options. Rare diseases are often serious, chronic and progressive. Orphan drugs are medicinal products intended for the diagnosis, prevention or treatment of rare
Mesothelioma: The “Orphan” Cancer
Government funding remains elusive for deadly disease Newton, MA. Oct. 1st 2007. While Americans have long been romanced by campaigns for breast cancer and leukemia research, it may be some time before mesothelioma enjoys a stint in the spotlight. Despite the fact that over 2,500 cases of the disease are diagnosed in the U.S. each year—with as many or more dying from it—the need to develop effective treatments for mesothelioma victims